Spondyloarthritis & psoriatic arthritis
Residual Disease Activity and Burden of Disease in Canadian Patients With Axial Spondyloarthritis: Results From a Multiregistry Analysis (UNISON-Axial SpA)
Authors' conclusion
This analysis demonstrated that most Canadians with axSpA failed to achieve sustained LDA after 12 months of initiating their latest therapy and confirms a high unmet need for additional treatments.
Study context
- Population
- Canadian patients with axial spondyloarthritis (axSpA) in three registries
- Participants
- 980 patients
- Exposure
- Rhumadata vs Spondyloarthritis Research Consortium of Canada (SPARCC) vs FORCAST
- Rhumadatan = 488
- SPARCCn = 239
- FORCASTn = 253
- Outcome
- Proportion failing to achieve sustained low disease activity (LDA) (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <3 at both 6 and 12 months after most recent treatment change)
- Follow-up
- 12 months
Methodological detailsobservational, multiregistry
- Observational
- Multiregistry
Main finding
As reported in the abstract
Failure to achieve sustained LDA
Observational data: associations, not effects.
Further findings
Failure to achieve LDA (BASDAI <3) · 6 months after treatment initiation
Pain
- Pain persisted in nearly half of all patients
Original publication
Residual Disease Activity and Burden of Disease in Canadian Patients With Axial Spondyloarthritis: Results From a Multiregistry Analysis (UNISON-Axial SpA). J Rheumatol. Published 1 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →